Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $4.4 million.

  • Bioventus' Other Accumulated Expenses rose 1248.09% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 1248.09%. This contributed to the annual value of $3.9 million for FY2024, which is 1866.69% down from last year.
  • Latest data reveals that Bioventus reported Other Accumulated Expenses of $4.4 million as of Q3 2025, which was up 1248.09% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' Other Accumulated Expenses ranged from a high of $10.2 million in Q2 2021 and a low of $3.0 million during Q4 2021
  • Over the past 5 years, Bioventus' median Other Accumulated Expenses value was $4.0 million (recorded in 2021), while the average stood at $4.4 million.
  • In the last 5 years, Bioventus' Other Accumulated Expenses tumbled by 6136.21% in 2022 and then soared by 3537.67% in 2023.
  • Bioventus' Other Accumulated Expenses (Quarter) stood at $3.6 million in 2021, then rose by 1.38% to $3.6 million in 2022, then soared by 33.52% to $4.8 million in 2023, then fell by 18.67% to $3.9 million in 2024, then grew by 12.51% to $4.4 million in 2025.
  • Its Other Accumulated Expenses was $4.4 million in Q3 2025, compared to $4.4 million in Q2 2025 and $4.4 million in Q1 2025.